Empros Pharma's Breakthrough: Over 8% Weight Loss in Novel Oral Agent Trial

Empros Pharma announces breakthrough in obesity treatment with phase-2b trial, revealing over 8% weight loss with a novel oral agent. A potential game-changer in weight management.